

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
  - TEXT CUT OFF AT TOP, BOTTOM OR SIDES
  - FADED TEXT
  - ILLEGIBLE TEXT
  - SKEWED/SLANTED IMAGES
  - COLORED PHOTOS
  - BLACK OR VERY BLACK AND WHITE DARK PHOTOS
  - GRAY SCALE DOCUMENTS
- 

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**



Eur päisch s Pat ntamt  
European Patent Office  
Office européen des brevets



Publication number:

**0 469 348 A2**

12

## EUROPEAN PATENT APPLICATION

21 Application number: **91111413.0**

51 Int. Cl.<sup>5</sup>: **C12N 15/51, C12Q 1/70**

22 Date of filing: **09.07.91**

30 Priority: **11.07.90 JP 183512/90**  
**18.12.90 JP 412177/90**  
**30.01.91 JP 29364/91**  
**14.02.91 JP 42855/91**

43 Date of publication of application:  
**05.02.92 Bulletin 92/06**

84 Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IT LI LU NL SE**

71 Applicant: **SHIONOGI SEIYAKU KABUSHIKI**  
**KAISHA trading under the name of**  
**SHIONOGI & CO., LTD.**  
**12-4, Saigisu 5-chome**  
**Fukushima-ku, Osaka 553(JP)**

72 Inventor: **Kamada, Takenobu, Osaka**  
**University**  
**Dep. of Medicine, 1-1-50, Fukushima**  
**Fukushima-ku, Osaka-shi, Osaka(JP)**  
Inventor: **Hayashi, Norio, Osaka University**  
**Dep. of Medicine, 1-1-50, Fukushima**  
**Fukushima-ku, Osaka-shi, Osaka(JP)**  
Inventor: **Mita, Eiiji, Osaka University**  
**Dep. of Medicine, 1-1-50, Fukushima**  
**Fukushima-ku, Osaka-shi, Osaka(JP)**  
Inventor: **Ueda, Keiji, Osaka University**  
**Dep. of Medicine, 1-1-50, Fukushima**  
**Fukushima-ku, Osaka-shi, Osaka(JP)**

74 Representative: **Vossius & Partner**  
**Siebertstrasse 4 P.O. Box 86 07 67**  
**W-8000 München 86(DE)**

54 **cDNA sequence and detection of hepatitis C virus.**

57 From sera and excised livers of HCV-antibody positive patients, cDNA derived from hepatitis C virus was isolated and sequenced. Also, on the basis of the sequence determined, the method for the detection of hepatitis C virus by the PCR technique was established.

According to the isolation and sequencing of the hepatitis C virus cDNA, it became possible to achieve the detection of hepatitis C virus by the PCR technique.

**EP 0 469 348 A2**

The present invention relates to a DNA sequence comprising a cDNA sequence derived from hepatitis C virus, which is designated by SEQ ID NO: 1, SEQ ID NO: 5, or SEQ ID NO: 10. The DNA sequence of the present invention is useful for the design and synthesis of probes and primers to be used in the RNA diagnosis of hepatitis C virus. This DNA sequence is also useful for the production of peptides to be used in the immunodiagnosis of hepatitis C by genetic engineering. Further, the peptides produced by genetic engineering with the use of this DNA sequence are useful for the production of antibodies to be used in the immunodiagnosis of hepatitis C.

The present invention also provides a method for the detection of hepatitis C virus, which is based on the PCR technique characterized by using one primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 2 and the other primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 3; or by using one primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 15 and the other primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 16.

Hepatitis A is an acute infectious disease which is caused by RNA virus of 27 nm in diameter and exhibits a good prognosis. Hepatitis A virus is present in liver parenchymal cells and stellate cells, and is excreted into feces so that they spread by oral infection. Because the period that the virus appears in blood is quite short, no infection is observed by way of blood. As compared with the acute hepatitis caused by other hepatitis viruses, the onset of this hepatitis is frequently accompanied by an attack of fever up to 38°C or more. In the majority of cases, the function of the liver will return to the normal conditions in about 40 days, although it may exhibit the rare progression to fulminant hepatitis.

Hepatitis B is caused by infection of hepatitis B virus. This virus falls under the category of DNA virus and has a double structure that consists of an envelope containing an HBs antigen and a core containing an HBc antigen. Infection of hepatitis B includes transient infection and persistent infection. In the case of transient infection, after the latent period of 1 to 6 months from the infection of hepatitis B virus, an increase in the serum GOT and GPT, as well as jaundice, will appear together with hepatic symptoms consisting mainly of gastrointestinal symptoms. In most cases, the function of the liver will return to the normal conditions within 3 months after the onset of this disease; however, there are some cases where it may become fulminant hepatitis and exhibit the rapid progression to death. In the case of persistent infection, primary infection of hepatitis B virus may change to the persistent infection, or symptomatic carriers may suddenly exhibit symptoms of hepatitis. In this case, acute hepatitis with typical symptoms is rarely observed, while the insidious approach of chronic hepatitis or liver cirrhosis is frequently observed.

Non-A, non-B hepatitis is that other than hepatitis A and hepatitis B among the post-transfusion hepatitis and sporadic acute hepatitis which is believed to be caused by a virus, and non-A, non-B hepatitis has been considered to be caused by unknown viruses. In Japan, post-transfusion hepatitis occurs in a probability of from 13% to 20%, and non-A, non-B hepatitis accounts for 90% or more of these cases. Non-A, non-B hepatitis has a stronger tendency to become chronic than hepatitis B. In many cases, the symptoms of this hepatitis are more anicteric and further lack subjective symptoms as compared with hepatitis A and hepatitis B (Menekigaku Yougo Jiten, Second edition, SAISHIN-IGAKU Publishing Co., Ltd.).

As described above, non-A, non-B hepatitis has been considered as the hepatitis which will be caused by unknown viruses. Recently, Houghton et al. (EPO Pub. No. 0 318 216) have succeeded in isolating a part of cDNA derived from the genome of non-A, non-B hepatitis virus by screening the expression products from a cDNA library which was obtained from the infected tissue and sera of patients with non-A, non-B hepatitis, and this hepatitis virus was named hepatitis C virus (HCV). Further, Kubo et al. (Nucleic Acids Research, 24 (1989) 10367-10372) has succeeded in isolating a part of cDNA derived from the genome of HCV different from the above-mentioned HCV.

As described above, it has been suggested that HCV is not a single virus and there are many subtypes of HCV. It has also been suggested that there are different subtypes of HCV depending upon the areas. Accordingly, for the purpose of attaining the accurate diagnosis, prevention of transmission, and treatment of hepatitis C, as well as its elucidation, HCV of an additional subtype should be isolated. A method for detecting HCV of such a subtype is also required.

The objective of the present invention is to provide a cDNA derived from an HCV of the subtype which is different from that of the known HCV. The DNA sequence of the present invention comprises the HCV cDNA sequence designated by SEQ ID NO: 1, SEQ ID NO: 5, or SEQ ID NO: 10 and more particularly, it consists of the DNA sequence designated by SEQ ID NO: 1, SEQ ID NO: 5, or SEQ ID NO: 10. The DNA sequence of the present invention is useful for the design and synthesis of probes and primers to be used in the RNA diagnosis of HCV, and also useful for the production of peptides to be used in the immunodiagnosis of hepatitis C by genetic engineering. Further, the peptides produced by genetic

engineering with the use of this DNA are also useful for the production of antibodies to be used in the immunodiagnosis of hepatitis C. Because the DNA sequence is different from the known HCV cDNA, the DNA sequence of the present invention is particularly useful for the diagnosis of hepatitis C which cannot be detected with reference to the known HCV cDNA sequence. In addition, from the comparison between the DNA sequence of the present invention and the known cDNA, if primers and probes with a higher homology to the both are prepared, it becomes possible to conduct the extensive RNA diagnosis of hepatitis C.

The present invention further provides a method for the detection of hepatitis C viruses which is based on the PCR technique characterized by using a primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 2 and a primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 3; or by using a primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 15 and a primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 16.

The HCV cDNA of the present invention is isolated according to the following process.

#### (1) RNA extraction

The pellets obtained from sera of HCV-antibody positive patients by ultracentrifugation or normal portions of the removed liver of a patient with liver cancer are homogenized in an appropriate buffer such as GIT buffer, followed by ultracentrifugation, and the resulting pellets are dissolved in an appropriate buffer such as TE buffer, after which RNA is extracted by phenol extraction and ethanol precipitation.

#### (2) Reverse transcription

The RNA obtained in Item (1) and an anti-sense primer synthesized on the basis of the known HCV cDNA sequence are allowed to react with a commercially available reverse transcriptase, thereby attaining reverse transcription.

#### (3) Polymerase chain reaction

To the reaction solution obtained in Item (2), a sense primer synthesized on the basis of the known HCV cDNA sequence and Taq DNA polymerase are added, and the polymerase chain reaction is conducted according to a conventional procedure.

#### (4) Second PCR

As occasion demands, PCR product obtained in (3) is again subjected to PCR using sense/anti-sense primers different from or same as those used in (3).

#### (5) Electrophoresis

The first or second PCR product is subjected to electrophoresis by use of a polyacrylamide gel or the like, and a band having a chain length which is deduced from the primer used is cut out, thereby obtaining DNA having the desired chain length.

#### (6) Cloning

The DNA obtained in Item (5), preferably phosphorylated at 5' ends, is inserted into a commercially available plasmid containing an appropriate selection marker, and the resulting plasmid is introduced into a suitable host such as *Escherichia coli*. The chain length of a plasmid DNA insert contained in transformants is determined, and clones containing the DNA insert of the desired chain length are identified as positive.

#### (6) Sequencing

The base sequence of the DNA insert in the positive clone is determined by the conventional dideoxy chain termination method.

The base sequence of the cDNA of the present invention is designated by SEQ ID NO: 1, SEQ ID NO:

5, or SEQ ID NO: 10. From the comparison between the cDNA sequence of the present invention (SEQ ID NO: 1) and the HCV cDNA sequence previously reported (J1: Nucleic Acid Research, 24 (1989) 10367-10372, and PT: EPO Pub. No. 0 318 216), it was found that M16 (SEQ ID NO: 1) of the present invention showed about 96% and about 81% homology to J1 and PT, respectively, from which the present inventors inferred that M16 would be a part of a novel HCV cDNA. Further, the base sequences of SEQ ID NO: 5 and SEQ ID NO: 10 are identified as novel.

The present invention further provides a method for the detection of hepatitis C viruses which is based on the PCR technique characterized by using a primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 2 and a primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 3; or by using a primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 15 and a primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 16.

The DNA sequence designated by SEQ ID NO: 2 is an anti-sense sequence corresponding to bases 604-623 of the DNA sequence designated by SEQ ID NO: 1, while the DNA sequence designated by SEQ ID NO: 3 is a sense sequence corresponding to bases 1-20 of the DNA sequence designated by SEQ ID NO: 1.

The DNA sequence designated by SEQ ID NO: 15 is an anti-sense sequence corresponding to bases 309-328 of the DNA sequence designated by SEQ ID NO: 10, while the DNA sequence designated by SEQ ID NO: 16 is a sense sequence corresponding to bases 9-28 of the DNA sequence designated by SEQ ID NO: 10.

The primers used in the method for the detection of hepatitis C virus according to the present invention are not limited to the DNA sequences designated by SEQ ID NO: 2 and SEQ ID NO: 3 or SEQ ID NO: 15 and SEQ ID NO: 16, and those composed of from 15 to 45 bases including at least 15 continuous bases of these DNA sequences can also be used. A chain length of from 15 to 40 bases is conventional for primers to be used in the PCR technique. It is also possible to use a combination of primers complementary to the DNA sequences described by SEQ ID NO: 2 and SEQ ID NO: 3 or SEQ ID NO: 15 and SEQ ID NO: 16. The design and preparation of such primers can be conveniently achieved on the basis of the DNA sequence described by SEQ ID NO: 1 or SEQ ID NO: 10 so that the DNA sequence described by SEQ ID NO: 1 or SEQ ID NO: 10 can be specifically detected by the PCR technique.

As the PCR technique used in the present invention, preferred is a reverse transcription-polymerase chain reaction (RT-PCR) method in which reverse transcription is carried out prior to PCR, because hepatitis C virus falls under the category of RNA virus.

The detection of PCR products can be achieved by subjecting to electrophoresis by use of a gel and southern hybridization using a probe corresponding to SEQ ID NO: 1, e.g., a probe of the sequence described by SEQ ID NO: 4; or a probe corresponding to SEQ ID NO: 10, e.g., a probe of the sequence described by SEQ ID NO: 17 which corresponds to bases 83-106 shown in SEQ ID NO: 10. In place of the southern hybridization, PCR product can be detected by subjecting to double PCR in which first PCR product is again subjected to PCR, electrophoresing the product with the use of a gel containing ethidium bromide, and detecting under ultraviolet light.

The present invention will be further illustrated by reference to the following example; however, this example is not intended to restrict the scope of the present invention.

#### EXAMPLE

##### Example 1

###### (1) RNA extraction

Sera from ten HCV-antibody positive patients at each volume of about 2 ml (the total volume being about 20 ml) were diluted 7 times with a TEN buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.1 M NaCl), and then pelleted by ultracentrifugation at 36,000 rpm for 2 hours at 15°C with an HITACHI RPS40T2 rotor. The resulting pellets and about 1 g of normal portions of the removed liver of HCV-antibody positive patients with liver cancer were homogenized in 40 ml of GIT buffer (4.0 M guanidinium thiocyanate, 0.1 M Tris-HCl (pH 7.8), 1%  $\beta$ -mercaptoethanol, and 0.5% sodium N-lauroylsarcosinate) with a blender (manufactured by KINEMATIC Co.) at the maximum speed for about 30 seconds.

Next, 20 ml of the homogenized solution was slowly overlaid over 20 ml of 5.7 M CsCl-0.01 M EDTA (pH 8.0), and then subjected to ultracentrifugation with a HITACHI SRP-28SA rotor at 24,000 rpm for 24

hours at 15°C. Then, about 800 µg of the resulting pellets was dissolved in a diethylpyrocarbonate-treated TE buffer (10 mM Tris-HCl (pH 7.8) and 1 mM EDTA), and extracted with phenol/chloroform/isoamylalcohol (24:24:1), followed by ethanol precipitation.

The resulting precipitate was dissolved in a diethylpyrocarbonate-treated TE buffer; after the concentration of nucleic acid was determined, the solution obtained was adjusted to an RNA concentration being 1 µg per µl of TE buffer; and the adjusted solution was used for the subsequent reverse transcription.

## (2) Reverse transcription

First, 1 µl of RNA (1 µg/µl TE buffer) obtained in the above-mentioned step (1) was mixed with a reaction solution of the composition:

10 × reaction buffer*	2 µl
dNTP (2.5 mM each)	8 µl
Sterilized distilled water	6 µl
Anti-sense primer (10 pmol/µl)**	2 µl

\* : Composition of the 10 × reaction buffer

500 mM KCl

100 mM Tris-HCl (pH 8.3) at 25°C

15 mM MgCl<sub>2</sub>

0.1% (W/V) gelatin

\*\* : Sequence of the anti-sense primer (SEQ ID NO: 2)

5'-GGCTATACCGGCGACTTCGA-3'

(synthesized by Cyclone manufactured by Bioresearch Co.)

See Nucleic Acid Research, 24 (1989) 10367-10372.

The above-mentioned reaction solution was preheated at 65°C for 5 minutes to release the secondary structure of RNA, after which the solution was allowed to stand at room temperature for 5 minutes to anneal the primer. To this solution, 1 µl of 200 units/µl M-MLV reverse transcriptase (Bethesda Research Laboratories) was added, and reverse transcription was conducted at 37°C for 60 minutes.

## (3) Polymerase chain reaction (PCR)

To 20 µl of the reaction solution obtained in the above-mentioned step (2), the following solution was added.

10 × reaction buffer	8 $\mu$ l
Sterilized distilled water	69 $\mu$ l
5 Sense primer (10 pmol/ $\mu$ l)*	2 $\mu$ l
Taq DNA polymerase (4 units/ $\mu$ l)**	1 $\mu$ l

\* : Sequence of the sense primer (SEQ ID NO: 3)

5'-GACATGCATGTCATGATGTA-3'

(synthesized by Cyclone manufactured by Bioresearch Co.)

See Nucleic Acid Research, 24 (1989) 10367-10372.

\*\* : "Gene Amp<sup>TM</sup>" kit (Takara Shuzo CO.)

The PCR was conducted 30 cycles under the conditions of temperature, 94°C for 30 seconds, 55°C for 1 minute, and 72°C for 1 minute, followed by additional treatment at 72°C for 15 minutes.

#### (4) Electrophoresis

First, 100  $\mu$ l of the PCR product was extracted with 100  $\mu$ l of phenol/chloroform/isoamylalcohol (24:24:1), followed by ethanol precipitation. Then, about 500 ng of the precipitate was suspended in 10  $\mu$ l of TE buffer, to which bromophenol blue/xylene cyanol/sucrose (4  $\mu$ l) was added, thereby obtaining a sample.

Separately, 2.8 ml of 30% acrylamide solution (29% acrylamide and 1% N, N'-methylene-bis-acrylamide), 2.4 ml of 10 × TBE buffer (890 mM Tris-boric acid and 20 mM EDTA (pH 8.0)), and 18.8 ml of sterilized distilled water were mixed together, to which a small amount of ammonium persulfate and 20  $\mu$ l of N, N, N', N'-tetramethylethylenediamine were added, thereby obtaining 3.5% polyacrylamide gel.

Using this gel, the above-mentioned sample was subjected to electrophoresis, after which double-stranded DNA was stained with ethidium bromide and observed under ultraviolet light. At the same time, as size markers, AluI-digested pBR322 (containing 908 bp, 659 bp, 656 bp, or 521 bp fragments) was subjected to electrophoresis. The desired band near the position corresponding to 623 bp which was deduced from the primer used (single band) was cut out and dissolved in 20  $\mu$ l of TE buffer.

#### (5) Cloning

First, 1  $\mu$ l of 2  $\mu$ g/ $\mu$ l pBluescript II SK+ (manufactured by Stratagene Co.) was mixed with 2  $\mu$ l of a reaction mixture (containing 100 mM Tris-HCl, 70 mM MgCl<sub>2</sub>, 200 mM KCl, 70 mM 2-mercaptoethanol, and 1 mg/ml bovine serum albumin), 16  $\mu$ l of sterilized distilled water, and 1  $\mu$ l of SmaI (14 unit/ $\mu$ l, manufactured by Toyobo Co.), and the mixture was incubated at 30°C for 1 hour to digest with SmaI, followed by phenol extraction and ethanol precipitation, after which the resulting precipitate was suspended in a TE buffer (final concentration, 0.1  $\mu$ g/ $\mu$ l).

Then, 1  $\mu$ l of the SmaI-digested pBluescript II SK+ solution was mixed with 6  $\mu$ l of the DNA solution obtained in the above-mentioned step (4), 2  $\mu$ l of 5 × ligation buffer (250 mM Tris-HCl (pH 7.8), 50 mM MgCl<sub>2</sub>, 50 mM dithiothreitol, 2.5 mM ATP, and 500  $\mu$ g/ml bovine serum albumin), and 1  $\mu$ l of T<sub>4</sub> DNA ligase (5 units/ $\mu$ l), and the mixture was incubated at 16°C for 20 hours.

Ca<sup>++</sup>-treated E. coli XL-1-B (100  $\mu$ l) was mixed with the above-mentioned reaction mixture (1  $\mu$ l), and the mixture was allowed to stand on ice at 0°C for 30 minutes, followed by transformation on an L plate containing 40  $\mu$ g/ml X-gal, 40  $\mu$ g/ml IPTG, and 50  $\mu$ g/ml ampicillin.

The transformed white colonies were incubated overnight in 5 ml of L medium. A 1.5 ml portion of this culture was centrifuged at 7000 rpm for 40 seconds. The resulting pellets was suspended in 100  $\mu$ l of a STET buffer (8% sucrose, 5% Triton X-100, 50 mM EDTA, and 50 mM Tris-HCl (pH 8.0)). To this suspension, 10  $\mu$ l of 10  $\mu$ g/ $\mu$ l lysozyme was added, and the mixture was boiled for 40 seconds. The mixture was then extracted with an equal volume of phenol/chloroform/isoamylalcohol (24:24:1), after which

an equal volume of isopropanol was added to the resulting supernatant and the mixture was allowed to stand at -20 °C for 30 minutes. After centrifugation (15,000 rpm, 4 °C, 10 minutes), the resulting pellets were suspended in 100 µl of a TE buffer. To 16 µl of this suspension, 2 µl of 10 × High buffer (500 mM Tris-HCl (pH 7.5), 1000 mM NaCl, 100 mM MgCl<sub>2</sub>, and 10 mM dithiothreitol), 1 µl of BamHI (12 units/µl), and 1 µl of EcoRI (12 units/µl) were added, and the mixture was incubated at 37 °C for 30 minutes, resulting in a double digestion with BamHI and EcoRI. To 20 µl of this reaction mixture, bromophenol blue/xylene cyanol/sucrose (5 µl) was added, and the mixture was subjected to electrophoresis using a 1.2% agarose gel. As a size marker, AluI-digested pBR322 was used. After staining with ethidium bromide, 2 positive clones were obtained from a band appearing around the desired size of 623 bp by observation under ultraviolet light.

#### (6) Sequencing

The base sequence of a DNA insert of M16, which is one of the positive clones obtained in the above-mentioned step (5), was determined by the dideoxy chain termination method. The base sequence determined is shown in the sequence listing, SEQ ID NO. 1. From the comparison between the DNA sequence of the present invention and the previously reported HCV cDNA sequence (J1: Nucleic Acid Research, 24 (1989) 10367-10372, and PT: EPO Pub. No. 0 318 216), M16 obtained in the present invention showed about 96% and about 81% homology to J1 and PT, respectively, and it was presumed to be a part of a novel HCV cDNA.

#### Example 2

##### (1) RNA extraction

About 1 g of normal portions of the removed liver of a patient with liver cancer was homogenized in 40 ml of GIT buffer (4.0 M guanidinium thiocyanate, 0.1 M Tris-HCl (pH 7.8), and 1% β-mercaptoethanol) with a blender (manufactured by KINEMATIC Co.) at the maximum speed for about 30 seconds. To this homogenized solution is added 10% sodium N-lauroylsarcosinate solution to give its final concentration of 0.5 %.

Next, 20 ml of the solution was slowly overlaid over 20 ml of 5.7 M CsCl-0.01 M EDTA (pH 8.0), and then subjected to ultracentrifugation with a HITACHI SRP-28SA rotor at 24,000 rpm for 24 hours at 15 °C. Then, the resulting pellet was dissolved in a diethylpyrocarbonate-treated TE buffer (100 mM Tris-HCl (pH 7.8) and 1 mM EDTA), and extracted with phenol/chloroform/isoamylalcohol (24:24:1), followed by ethanol precipitation.

The resulting precipitate was dissolved in 300 µl of a diethylpyrocarbonate-treated TE buffer. Its concentration of nucleic acid was determined. The RNA concentration was 2.8 µg/µl TE buffer.

##### (2) Reverse transcription

First, 1 µl of RNA (2.8 µg/µl) obtained in the above-mentioned step (1) was mixed with a reaction solution of the composition:

10 × reaction buffer \* 2 µl

Sterilized distilled water 12 µl

Anti-sense primer (10 pmol/µl) \*\* 2 µl

The above-mentioned reaction solution was preheated at 65 °C for 5 minutes to release the secondary structure of RNA, after which the solution was allowed to stand at room temperature for 2 minutes to anneal the primer. To this solution, the following solution was added, and reverse transcription was conducted at

\* : Composition of the 10 × reaction buffer

500 mM KCl

100 mM Tris-HCl (pH 8.3) at 25 °C

15 mM MgCl<sub>2</sub>

0.1% (W/V) gelatin

\*\* : Sequence of the anti-sense primer

5'-AAGATAGAGAAAGAGCAACC 3' (SEQ ID NO: 6)

See Japan. J. Exp. Med., 60 (1990) 167-177

42 ° C for 60 minutes.

dNTP (10 mM each) 2 $\mu$ l	
RNase inhibitor (40 units/ $\mu$ l)* 0.5	$\mu$ l
MMuLV reverse transcriptase (200 units/ $\mu$ l)** 0.5	$\mu$ l

\*: Promega Co.

\*\*: Bethesda Research Laboratories

### (3) Polymerase chain reaction (PCR)

To 20  $\mu$ l of the reaction solution obtained in the above-mentioned step (2), the following solution was added.

10 $\times$ reaction buffer	8 $\mu$ l
Sense primer (10 pmol/ $\mu$ l)*	2 $\mu$ l
Sterilized distilled water	69.5 $\mu$ l
Taq DNA polymerase (4 units/ $\mu$ l)**	0.5 $\mu$ l

\* : Sequence of the sense primer

5'-CICGTAGACCGTGCACCAIG-3' (SEQ ID NO: 7)

See Japan. J. Exp. Med., 60 (1990) 167-177

\*\*: "Gene Amp™" kit (Takara Shuzo CO.)

The PCR was conducted 30 cycles with 1 cycle being  
denaturation: 94 ° C for 30 seconds,  
annealing: 55 ° C for 1 minute, and  
extension: 72 ° C for 1 minute,  
followed by additional treatment at 72 ° C for 15 minutes.

### (4) Second PCR

To 5  $\mu$ l of the reaction solution obtained in the above-mentioned step (3), the following solution was added.

	10 × reaction buffer	10 $\mu$ l
	dNTP (10 mM each)	2 $\mu$ l
5	Sense primer (10 pmol/ $\mu$ l)*	2 $\mu$ l
	Anti-sense primer (10 pmol/ $\mu$ l)**	2 $\mu$ l
10	Sterilized distilled water	78.5 $\mu$ l
	Taq DNA polymerase***	0.5 $\mu$ l

15 \* : Sequence of the sense primer

5'-ACCAAACGTAACACCAACCG-3' (SEQ ID NO: 8)

20 See Japan. J. Exp. Med., 60 (1990) 167-177

\*\* : Sequence of the anti-sense primer

25 5'-GTTCATAGTTCAGCCGTC-3' (SEQ ID NO: 9)

See Japan. J. Exp. Med., 60 (1990) 167-177

30 \*\*\* : The same as used in the above step (2).

The PCR was conducted 30 cycles with 1 cycle being  
 35 denaturation: 94 °C for 30 seconds,  
 annealing: 55 °C for 1 minute, and  
 extension: 72 °C for 1 minute,  
 followed by additional treatment at 72 °C for 15 minutes.

#### 40 (5) Electrophoresis

To 60  $\mu$ l of the PCR product of the above step (4) was added bromophenol blue/xlenecyanol/sucrose (20  $\mu$ l), which was electrophoresed with the use of an agarose gel (Sea Plaque, FMC) and stained with ethidium bromide. Double-stranded DNA was observed under ultraviolet light. At the same time, as a size  
 45 marker, AluI-digested pBR322 (containing 908 bp, 659 bp, 656 bp, or 521 bp fragments) was subjected to electrophoresis. With reference to these bands, a single band of the desired length was cut out, DNA in which was recovered according to the method of Sambrook et al. (Molecular cloning, Cold Spring Harbour Laboratory (CSHL) Press).

#### 50 (6) Cloning

##### Kination

A solution (10  $\mu$ l) of 0.2  $\mu$ g/ $\mu$ l DNA obtained in the above step (5) in TE buffer was mixed with the  
 55 following solutions.

5 × Kination buffer*	4 µl
ATP (50 pmol/µl)	2 µl
Sterilized distilled water	2 µl
T <sub>4</sub> polynucleotide kinase (10 units/µl)**	2 µl

\*: Composition of 5 × Kination buffer

250mM Tris-HCl (pH 9.5)

50mM MgCl<sub>2</sub>

25mM DTT

25% glycerol

\*\* : Bio Labs.

The mixture obtained above was allowed to react at 37 °C for 30 minutes, to which was added 2 µl of T<sub>4</sub> polynucleotide kinase. This was further allowed to react at 37 °C for 30 minutes to phosphorylate DNA at 5' ends.

The resultant was treated with phenol and precipitated with ethanol.

#### Ligation

A solution (1 µl) of 0.05 µg/µl of the precipitate obtained by the above ethanol-precipitation in TE buffer was mixed with the following solutions.

5 × ligation buffer*	2 µl
CIAP-treated/SmaI-digested-pBluescript II SK(+)**	1 µl
Sterilized distilled water	5 µl
T <sub>4</sub> DNA ligase (5 units/µl)	1 µl

\*: Composition of 5 × ligation buffer

250 mM Tris-HCl (pH 7.8)

50 mM MgCl<sub>2</sub>

50 mM dithiothreitol

2.5 mM ATP

500 µg/ml bovine serum albumin

\*\* : pBluescript II SK(+) (Stratagene) completely digested with SmaI, dephosphorylated with calf intestinal alkaline phosphatase according to the method of Sambrook et al. (Molecular cloning, CSHL Press), and dissolved in TE buffer to give a concentration of 0.1 µg/µl.

This mixture was allowed to react at 16 °C for 24 hours.

#### Transformation

Ca<sup>++</sup>-treated E. coli XL-1-B (100 µl) was mixed with the above-mentioned reaction mixture (1 µl), and the mixture was allowed to stand on ice at 0 °C for 30 minutes, followed by transformation on an L plate containing 40 µg/ml X-gal, 40 µg/ml IPTG, and 50 µg/ml ampicillin.

The transformed white colonies were incubated overnight in 5 ml of L medium. A 1.5 ml-portion of this culture was centrifuged at 7000 rpm for 40 seconds. The resulting pellets was suspended in 100 µl of a STET buffer (8% sucrose, 5% Triton X-100, 50 mM EDTA 50 mM Tris-HCl (pH 8.0)). To this suspension, 10 µl of 10 µg/µl lysozyme was added, and the mixture was boiled for 40 seconds. The mixture was then extracted with an equal volume of phenol/chloroform/isoamylalcohol (24:24:1), after which an equal volume of isopropanol was added to the resulting supernatant and the mixture was allowed to stand at -20 °C for 30 minutes. After centrifugation (15,000 rpm, 4 °C, 10 minutes), the resulting pellets were suspended in 100 µl of a TE buffer. To 16 µl of this suspension, 2 µl of 10 × High buffer (500 mM Tris-HCl (pH 7.5), 1000 mM NaCl, 100 mM MgCl<sub>2</sub>, and 10 mM dithiothreitol), 1 µl of BamHI (12 units/µl), and 1 µl of EcoRI (12 units/µl) were added, and the mixture was incubated at 37 °C for 1 hour, resulting in a double digestion with BamHI and EcoRI.

To 20 µl of this reaction mixture, bromophenol blue/ xylene cyanol/sucrose (5 µl) was added, and the

mixture was subjected to electrophoresis using a 1.2% agarose gel. As a size marker, AluI-digested pBR322 was used. After staining with ethidium bromide, a band of the desired length was observed under ultraviolet light. Clones corresponding to the band were identified as positive.

5 (7) Sequencing

The base sequence of a DNA insert of M20, which is one of the positive clones obtained in the above-mentioned step (6), was determined by the dideoxy chain termination method. The base sequence determined is shown in the sequence listing, SEQ ID NO: 5.

10

Example 3

(1) RNA extraction

15 About 1 g of normal portions of the removed liver of a patient with liver cancer was homogenized in 40 ml of GIT buffer (4.0 M guanidinium thiocyanate, 0.1 M Tris-HCl (pH 7.5), and 1%  $\beta$ -mercaptoethanol) with a blender (manufactured by KINEMATIC Co.) at the maximum speed for about 30 seconds. To this homogenized solution, 10 % sodium N-lauroylsarcosinate solution is added to give its concentration of 0.5 %.

20 Next, 20 ml of the solution was slowly overlaid over 20 ml of 5.7 M CsCl-0.01 M EDTA (pH 8.0), and then subjected to ultracentrifugation with a HITACHI SRP-28SA rotor at 24,000 rpm for 24 hours at 15 °C. The resulting pellet was dissolved in a diethylpyrocarbonate-treated TE buffer (100 mM Tris-HCl (pH 7.8) and 1 mM EDTA), and extracted with phenol/chloroform/isoamylalcohol (24:24:1), followed by ethanol precipitation.

25 The resulting precipitate was dissolved in 300  $\mu$ l of a diethylpyrocarbonate-treated TE buffer. The concentration of nucleic acid was determined. The RNA concentration was 2.8  $\mu$ g per  $\mu$ l TE buffer.

(2) Reverse transcription

30 First, 1  $\mu$ l of RNA (2.8  $\mu$ g/ $\mu$ l) obtained in the above-mentioned step (1) was mixed with a reaction solution of the composition:

	10 $\times$ reaction buffer*	2 $\mu$ l
35	Sterilized distilled water	12 $\mu$ l
	Anti-sense primer (10 pmol/ $\mu$ l)**	2 $\mu$ l

40

45

50

55

## \* : Composition of the 10 × reaction buffer

500 mM KCl

100 mM Tris-HCl (pH 8.3) at 25 °C

15 mM MgCl<sub>2</sub>

0.1% (W/V) gelatin

## \*\* : Sequence of the anti-sense primer

5'-AAGATAGAGAAAGAGCAACC -3' (SEQ ID NO: 11)

See Japan. J. Exp. Med. 60, (1990) 167-177

The above-mentioned reaction solution was preheated at 65 °C for 5 minutes to release the secondary structure of RNA, after which the solution was allowed to stand at room temperature for 2 hours to anneal the primer. To this solution the following solutions were added, and reverse transcription was conducted at 42 °C for 60 minutes.

dNTP (10 mM each)	2 μl
RNase inhibitor (40 units/μl)*	0.5 μl
MMuLV reverse transcriptase (200 units/μl)**	0.5 μl

\*: Promega Co.

\*\*: Bethesda Research Laboratories

## (3) Polymerase chain reaction (PCR)

To 20 μl of the reaction solution obtained in the above-mentioned step (2), the following solutions were added.

10 × reaction buffer 8 μl

Sense primer (10 pmol/μl)\* 2 μl

Sterilized distilled water 69.5 μl

Taq DNA polymerase (5 units/μl)\*\* 0.5 μl

## \* : Sequence of the sense primer

5'-GGCGACACTCCACCATAGAT-3' (SEQ ID NO: 12)

See Japan. J. Exp. Med. 60, (1990) 167-177

\*\*: "Gene Amp™" kit (Takara Shuzo Co.)

The PCR was conducted 30 cycles with one cycle being

Denaturation: 94 °C for 30 seconds,

Annealing: 55 °C for 1 minute, and

Extension: 72 °C for 1 minute,

5 followed by additional treatment at 72 °C for 15 minutes.

#### (4) Second PCR

To 5 µl of the reaction solution obtained in the above-mentioned step (3), the following solutions were  
10 added.

	10 × reaction buffer	10 µl
	dNTP (10 mM each)	2 µl
15	Sense primer (10 pmol/µl)*	2 µl
	Anti-sense primer (10 pmol/µl)**	2 µl
20	Sterilized distilled water	78.5 µl
	Taq DNA polymerase***	0.5 µl

25 \* : Sequence of the sense primer

5'-GGCGACACTCCACCATAGAT-3' (SEQ ID NO: 13)

30 See Japan. J. Exp. Med. 60, (1990) 167-177

\*\* : Sequence of the anti-sense primer

5'-CCGTGTTCCAGAACCCGGAC-3' (SEQ ID NO: 14)

35 See Japan. J. Exp. Med. 60, (1990) 167-177

\*\*\* : The same as used in the step (2).

40 The PCR was conducted 30 cycles with one cycle being

Denaturation: 94 °C for 30 seconds,

Annealing: 55 °C for 1 minute, and

Extension : 72 °C for 1 minute,

45 followed by additional treatment at 72 °C for 15 minutes.

#### (5) Electrophoresis

To 60 µl of the PCR product obtained in the above step (4) was added 20 µl of bromophenol blue/xylene cyanol/sucrose. This was subjected to electrophoresis using an agarose gel (Sea Plaque, FMC  
50 Co.), after which double-stranded DNA was stained with ethidium bromide and observed under ultraviolet light. At the same time, as a size marker, AluI-digested pBR322 (containing 908 bp, 659 bp, 656 bp, or 521 bp fragments) was subjected to electrophoresis. With reference to these fragments, a single band of the desired length was cut out. The DNA in the band was recovered according to the method of Sambrook et al. (Molecular cloning, Cold Spring Harbour Laboratory (CSHL) Press).

55

#### (6) Cloning

##### Kination

A solution (10  $\mu$ l) of 0.2  $\mu$ g/ $\mu$ l DNA obtained in the above step (5) in TE buffer was mixed with the following solutions.

5	5X Kination buffer*	4 $\mu$ l
	ATP (50 pmol/ $\mu$ l)	2 $\mu$ l
	Sterilized distilled water	2 $\mu$ l
10	T <sub>4</sub> polynucleotide kinase (10 units/ $\mu$ l)**	2 $\mu$ l

15 \*: Composition of 5X Kination buffer

	250 mM Tris-HCl (pH 9.5)
	50 mM MgCl <sub>2</sub>
20	25 mM DTT
	25 % glycerol

25

\*\* : Bio Labs.

30 The mixture obtained above was allowed to react at 37 °C for 30 minutes, to which was added 2  $\mu$ l of T<sub>4</sub> polynucleotide kinase. This was further allowed to react at 37 °C for 30 minutes to phosphorylate DNA at 5' ends.

The resultant was treated with phenol and precipitated with ethanol.

### 35 Ligation

A solution (1  $\mu$ l) of 0.05  $\mu$ g/ $\mu$ l of the precipitate obtained by the above ethanol-precipitation in TE buffer was mixed with the following solutions.

40	5 x ligation buffer*	2 $\mu$ l
	CIAP-treated/SmaI-digested-pBluescript II SK(+)**	1 $\mu$ l
	Sterilized distilled water	5 $\mu$ l
	T <sub>4</sub> DNA ligase (5 units/ $\mu$ l)	1 $\mu$ l

45 \*: Composition of 5 x ligation buffer

	250 mM Tris-HCl (pH 7.8)
	50 mM MgCl <sub>2</sub>
	50 mM dithiothreitol
	2.5 mM ATP

50 500  $\mu$ g/ml bovine serum albumin

\*\* : pBluescript II SK(+) (Stratagene) completely digested with SmaI, dephosphorylated with calf intestinal alkaline phosphatase according to the method of Sambrook et al. (Molecular cloning, CSHL Press), and dissolved in TE buffer to give a concentration of 0.1  $\mu$ g/ $\mu$ l.

55

This mixture was allowed to react at 16 °C for 24 hours.

### Transformation

Ca<sup>++</sup>-treated *E. coli* XL-1-B (100 µl) was mixed with the above-mentioned ligating reaction mixture (1 µl), and the mixture was allowed to stand on ice at 0 °C for 30 minutes, followed by transformation on an L plate containing 40 µg/ml X-gal, 40 µg/ml IPTG, and 50 µg/ml ampicillin.

The transformed white colonies were incubated overnight in 5 ml of an L medium. A 1.5 ml portion of this culture was centrifuged at 7000 rpm for 40 seconds. The resulting pellets were suspended in 100 µl of an STET buffer (8% sucrose, 5% Triton X-100, 50 mM EDTA, and 50 mM Tris-HCl (pH 8.0)). To this suspension, 10 µl of 10 µg/µl lysozyme was added, and the mixture was boiled for 40 seconds. The mixture was then extracted with an equal volume of phenol/chloroform/isoamylalcohol (24:24:1), after which an equal volume of isopropanol was added to the resulting supernatant and the mixture was allowed to stand at -20 °C for 30 minutes. After centrifugation (15,000 rpm, 4 °C, 10 minutes), the resulting pellet was suspended in 100 µl of a TE buffer. To 16 µl of this suspension, 2 µl of 10 × High buffer (500 mM Tris-HCl (pH 7.5), 1000 mM NaCl, 100 mM MgCl<sub>2</sub>, and 10 mM dithiothreitol), 1 µl of BamHI (12 units/µl), and 1 µl of EcoRI (12 units/µl) were added, and the mixture was incubated at 37 °C for 1 hour, resulting in a double digestion with BamHI and EcoRI.

To 20 µl of this reaction mixture, bromophenol blue/ xylene cyanol/sucrose (5 µl) was added, and the mixture was subjected to electrophoresis using a 1.2% agarose gel. As a size marker, AluI-digested pBR322 was used. After staining with ethidium bromide, a band around the desired length was observed under ultraviolet light. Clones corresponding to the band were identified as positive.

## 20 (7) Sequencing

The base sequence of a DNA insert of M642, which is one of the positive clones obtained in the above-mentioned step (6), was determined by the dideoxy chain termination method. The base sequence determined is shown in SEQ ID NO: 10.

25

## Example 4

### Detection of Hepatitis C Virus According to RT-PCR Method

30 An experiment of the following steps was carried out on 115 cases of non-A, non-B-type chronic liver disease and 10 cases of B-type chronic liver disease.

#### (1) RNA extraction

35 To 200 µl of serum of each patient mentioned above was added 100 µl of 21% PEG 6000 - 1.5M NaCl. This mixture was mixed by a tube mixer, vortex, centrifuged lightly, and allowed to stand in ice for 1 - 2 hours. After centrifugation with 15,000 rpm at 4 °C for 20 minutes (Tomy, Angle rotor) to remove the resulting supernatant, to the obtained precipitate was added 400 µl of GTC buffer (4M guanidinium thiocyanate, 0.1 M Tris-HCl (pH 7.5), 1% β- mercaptoethanol, and 0.5 % sarcosyl). After dissolving the precipitate by pipetting, this mixture was briefly centrifuged. To this was added 400 µl of phenol/ chloroform/isoamylalcohol (24:24:1). This mixture was mixed by vortex and centrifuged with 12,000 rpm at room temperature for 20 minutes (Tomy, Swing rotor) to recover the resulting supernatant (water layer).

To the supernatant was further added an equal volume of phenol/chloroform/ isoamylalcohol (24:24:1). This mixture was mixed by vortex and centrifuged with 12,000 rpm at room temperature for 20 minutes (Tomy, Swing rotor) to recover 300 µl of the resulting supernatant (water layer). To the supernatant was added 1 µl of tRNA (10 µg/µl), 1/10 volume (30 µl) of 3 M sodium acetate, and 2.5 volumes (750 µl) of cold ethanol. This mixture was allowed to stand at -80 °C for 1 hour or more and centrifuged with 15,000 rpm at 4 °C for 15 minutes (Tomy, Angle rotor) to obtain a precipitate. To the precipitate was added 200 µl of 70 % ethanol. This mixture was briefly mixed by vortex and centrifuged with 15,000 rpm at 4 °C for 10 minutes (Tomy, Angle rotor) to obtain a precipitate. The precipitate was dried in a vacuum in a desiccator, dissolved in RT solution I, heated at 65 °C for 10 minutes, and rapidly cooled in ice.

55

## \*: Composition of the RT solution I

Anti-sense primer (10 pmol/ $\mu$ l)\*\* 2  $\mu$ l  
 Sterilized distilled water 9  $\mu$ l  
 Total: 11  $\mu$ l

## \*\*: Sequence of the anti-sense primer

5'-CATGGTGCACGGTCTACGAG-3' (SEQ ID NO: 15)

## (2) Reverse Transcription (Synthesis of cDNA)

The solution obtained in the above step (1) was briefly mixed by vortex, to which RT solution II\* was added. This mixture was allowed to react at 37 °C for 30 minutes and then at 42 °C for 30 minutes, followed by brief centrifugation.

## \*: Composition of the RT solution II

5 × M-MLV RT Buffer (BRL)\*\* 4  $\mu$ l  
 0.1M DTT (BRL) 2  $\mu$ l

10mM dNTPs 2  $\mu$ l  
 RNase inhibitor (Promega, 40 units/ $\mu$ l) 0.5  $\mu$ l  
 M-MLV reverse transcriptase (BRL, 200 units/ $\mu$ l) 0.5  $\mu$ l  
 Total: 9  $\mu$ l

## \*\*: Composition of 5 × M-MLV RT Buffer (BRL)

250 mM Tris-HCl (pH 8.3, 25°C)  
 375 mM KCl  
 15 mM MgCl<sub>2</sub>

## (3) PCR

To 0.5 ml-ependorf tube was added PCR solution\*, to which was added 20  $\mu$ l of cDNA solution of the above step (2) which had been heated at 95 °C for 5 minutes and rapidly cooled in ice.

## \*: Composition of the PCR solution

1 × PCR buffer\*\* 77.5  $\mu$ l  
 5 Sense primer (10 pmol/ $\mu$ l)\*\*\* 2  $\mu$ l  
 Taq polymerase (CETUS, 5 units/ $\mu$ l) 0.5  $\mu$ l  
 10 Total: 80.0  $\mu$ l

## \*\*: Composition of the 1 × PCR buffer

45.16 mM KCl  
 15 1.16 mM MgCl<sub>2</sub>  
 0.01 % gelatin

## \*\*\*: Sequence of the sense primer

20 5'-ACTCCACCATAGATCACTCC-3' (SEQ ID NO: 16)

PCR was carried out 40 cycles with use of the solution obtained above and DNA Thermal Cycler  
 25 (CETUS), one cycle being

Denaturation: 94 °C for 30 seconds,

Annealing: 55 °C for 1 minute, and

Extension: 72 °C for 1 minute,

followed by further extension at 72 °C for 10 minutes.

30

## (4) Southern Blotting

The PCR product obtained in the above (3) was electrophoresed by using 2 % agarose gel without  
 35 ethidium bromide. The gel was immersed in 200 ml of 0.5 N NaOH - 1.5 M NaCl for 30 minutes with  
 shaking slowly. DNA in the gel was alkali-blotted overnight to a membrane (Amersham, Hybond-N+) with  
 use of 0.4 N NaOH as alkali trans buffer. The membrane was washed twice at room temperature for 15  
 minutes each with 2 × SSC with shaking slowly, further washed at 50 °C for 30 minutes, dried at room  
 temperature, and then preserved at -20 °C.

40 (5) Hybridization with <sup>32</sup>P-labeled HCV-cDNA

The membrane southern-blotted in the above (4) was immersed in a prehybridization solution (5 ×  
 SSPE, 5 × Denhardt's solution, 0.5 % SDS, and 100  $\mu$ g/ml ssDNA) at 55 °C for 2 - 4 hours. A <sup>32</sup>P-labeled  
 HCV-cDNA probe \* was added thereto. This was incubated overnight at 55 °C. The membrane was washed  
 45 with about 100 ml of 0.1 × SSC/0.1 % SDS solution at room temperature for 30 minutes with shaking slowly  
 and then with about 100 ml of 0.1 × SSC/0.1 % SDS solution at 50 °C for 30 minutes with shaking slowly  
 and subjected to autoradiography at -80 °C to detect HCV-RNA.

## (6) Detection of Antibody C-100

50

Independently of the above experiment, detection of antibody C-100 was carried out on the same  
 samples as used in the above experiment, using ELISA kit of Ortho Co.

## (7) Result

55

\*: Sequence of the <sup>32</sup>P-labeled HCV-cDNA probe  
 5'-GAGTGTCTGTCAGCCTCCAGGTCC-3' (SEQ ID NO: 17)

Antibody C-100-positive were 93 (81 %) of 115 cases of non-A, non-B type chronic liver disease. HCV-RNA was detected in 92 % (86/93) of antibody C-100-positive cases and 50 % (11/22) of antibody C-100 negative-cases but not in any case of B type chronic liver disease.

Independently, the same experiment was carried out on 20 cases of C type chronic liver diseases which was antibody C-100-positive. HCV-RNA-positive were 20 (100 %) of 20 cases.

Another experiment in the similar manner to the above was carried out on 20 samples.

From 100-500 µl each of sera obtained from patients with chronic hepatitis C (20 samples) which were positive for C-100 antibodies, RNA was extracted and precipitated with ethanol, followed by reverse transcription using an anti-sense primer of the sequence designated by SEQ ID NO: 2, resulting in a cDNA. Further, a sense primer of the sequence designated by SEQ ID NO: 3 was added and PCR was carried out 40 cycles. The PCR products were subjected to electrophoresis on a 2% agarose gel and blotted on a membrane, followed by hybridization analysis using <sup>32</sup>P-labeled DNA of the sequence designated by SEQ ID NO: 4 as a probe. The C-100 antibody was assayed with an ELISA kit available from Ortho Co.

As a result, 18 samples in the 20 samples exhibited HCV-RNA positive.

SEQUENCE LISTING

5

SEQ ID NO: 1

SEQUENCE LENGTH: 623 base pairs

10

SEQUENCE TYPE: nucleic acid

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid, cDNA derived from virus RNA

15

ANTI-SENSE: No

ORIGINAL SOURCE

ORGANISM: hepatitis C virus

20

## SEQUENCE DESCRIPTION

25

GGCTATACCG GCGACTTCGA CTCGGTGATC GACTGTAAACA CATGTGTCAC TCAGACGGTC 60

GATTTCAGCT TGGATCCAC CTTACCAATT GAGACGACGA CCGTGCCCCA AGATGCGGTG 120

TCGCGCACAC AGCGGCGAGG TAGGACTGGC AGAGGTAGGA GAGGCATCTA CAGGTTTGTG 180

30

ACTCCAGGGG AACGGCCCTC GGGCATGTTC GATTCTCGG TCCTGTGTGA GTGTTATGAC 240

GCGGGCTGCG CTTGGTATGA GCTTACGCCC GCTGAGACCT CGGTTAGGTI GCGGGCTTAC 300

CTAAATACAC CAGGGTTGCC CGTCTGCCAG GACCACTCTG AGTCTGGGA GAGCGCTCTC 360

35

ACAGGCCTCA CCCACATAGA TGCCCATTTT TTGTCCCAGA CCAAGCAGGC AGGAGACAAC 420

TTCCCCTACC TGGTAGCATA TCAAGCCACA GTGTGCGCCA GGGCTCAGGC TCCACCTCCA 480

TCGTGGGACC AAATGIGGAA GTATCTCACA CGGCTAAAAC CTACGCTGCA CGGGCCAACG 540

40

CCCCIGCTGT ATAGGCTAGG AGCCGTCCAA AATGAAGTCA TCCTACACA CCCCATAACC 600

AAATACATCA TGACATGCAT GTC 623

45

SEQ ID NO: 2

SEQUENCE LENGTH: 20 base pairs

50

SEQUENCE TYPE: nucleic acid

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid, synthesized DNA

55

ANTI-SENSE: Yes

## SEQUENCE DESCRIPTION

GACATGCA TG TCA TGATGTA

20

5

SEQ ID NO: 3

SEQUENCE LENGTH: 20 base pairs

10

SEQUENCE TYPE: nucleic acid

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid, synthesized DNA

15

ANTI-SENSE: No

## SEQUENCE DESCRIPTION

20

GGCTATACCG GCGACTTCGA

20

25

SEQ ID NO: 4

SEQUENCE LENGTH:

SEQUENCE TYPE: nucleic acid

30

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid, synthesized DNA

35

ANTI-SENSE: No

## SEQUENCE DESCRIPTION

40

GATCCCACTT TCACCATGTA GACGACGACC GTGCCCCAAG ATGCGGTGTC GCGCACACAG 60

CGGCCGAGGTA GGACTGGCAG AGGTAGGAGA GGCATCTACA GGTTTGTGAC TCCAGGGGAA 120

CGGCCCTCGG GCAIGTTCGA TTCCTCGGTC CIGTGTGAGT GTTATGACGC GGGCTGCGCT 180

45

TGGTATGAGC TIACGCCCCG IGAGACCTCG GTTAGGTTCG GGGCTTACCT AAATACACCA 240

GGGTGCCCCG ICTGCCAGGA CCATCTGGAG TTCIGGGAGA GCGTCTTCAC AGG 293

50

SEQ ID NO: 5

SEQUENCE LENGTH: 467 base pairs

55

SEQUENCE TYPE: nucleic acid

TOPOLOGY: linear

5 MOLECULE TYPE: Other nucleic acid, cDNA derived from virus RNA

ANTI-SENSE: No

ORIGINAL SOURCE

10 ORGANISM: hepatitis C virus

# SEQUENCE DESCRIPTION

15 ACCAAACGTA ACACCAACCG TCGCCACAG GACGTCAAGT TCCGGGCGG TGGTCAGATC 60  
 GTTGGTGGAG TTTACCTGTT GCCGCGCAGG GGCCCCAGGT TGGGTGTGCG CGCGACTAGG 120  
 AAGACTTCCG AGCGGTCCGA ACCTCGTGGG AGGCGACAAC CTATCCCCAA GGCTGCGCCG 180  
 20 CCCGAGGGCA GGGCCTGGGC TCAGCCCGGG TACCCTTGGC CCCTCTATGG CAATGAGGGT 240  
 CTGGGGTGGG CAGGATGGCT CTTGTACCCC CGAGGCTCTC GGCCTAGTTG GGGCCCCACT 300  
 GACCCCCGGC GTAGGTCGCG TAATTGGGT AAGGTCATCG ATACCCTCAC ATGCGGCTTC 360  
 25 GCCGACCTCA TGGGTACAT TCCGCTCGTC GCGCCCCCCC TGGGAGGCGC TGCCAGGGCC 420  
 CTGGCGCATG GCGTCCGGT TCTGGAGGAC GCGTGAACI ATGCAAC 467

30

SEQ ID NO: 6

SEQUENCE LENGTH: 20 base pairs

35

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: Single

TOPOLOGY: linear

40

MOLECULE TYPE: Other nucleic acid, synthesized DNA

ANTI-SENSE: Yes

45

# SEQUENCE DESCRIPTION

AAGATAGAGA AAGAGCAACC 20

50

SEQ ID NO: 7

SEQUENCE LENGTH: 20 base pairs

55

SEQUENCE TYPE: nucleic acid

5 STRANDEDNESS: Single  
 TOPOLOGY: linear  
 MOLECULE TYPE: Other nucleic acid, synthesized DNA  
 10 ANTI-SENSE: No

SEQUENCE DESCRIPTION  
 15 CTCGIAGACC GTGCACCAIG 20

SEQ ID NO: 8  
 20 SEQUENCE LENGTH: 20 base pairs  
 SEQUENCE TYPE: nucleic acid  
 STRANDEDNESS: Single  
 25 TOPOLOGY: linear  
 MOLECULE TYPE: Other nucleic acid, synthesized DNA  
 30 ANTI-SENSE: No

SEQUENCE DESCRIPTION  
 35 ACCAAACGTA ACACCAACCG 20

SEQ ID NO: 9  
 40 SEQUENCE LENGTH: 20 base pairs  
 SEQUENCE TYPE: nucleic acid  
 STRANDEDNESS: Single  
 45 TOPOLOGY: linear  
 MOLECULE TYPE: Other nucleic acid, synthesized DNA  
 50 ANTI-SENSE: Yes

SEQUENCE DESCRIPTION  
 55 GTTGCAIAGT TCACGCCGTC 20

SEQ ID NO: 10

SEQUENCE LENGTH: 807 base pairs

SEQUENCE TYPE: nucleic acid

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid, cDNA derived from virus RNA

ANTI-SENSE: No

ORIGINAL SOURCE

ORGANISM: hepatitis C virus

#### SEQUENCE DESCRIPTION

20	CCGGCGACAC TCCACCATAG ATCACTCCCC TGTGAGGAAC TACTGTCTTC ACGCAGAAAG	60
	CGICTIAGCCA TGGCGTTAGT ATGAGTGTG TGCAGCCTCC AGGTCCCCC TCCCGGGAGA	120
25	GCCATAGAGG TCTGCGGAAC CGGTGAGTAC ACCGGAATTG CCAGGACGAC CGGGTCTTTT	180
	CTTGGATCAA CCCGCTCAAT GCCTGGAGAT TTGGGCGTGC CCCC GCGAGA CTGCTAGCCG	240
	AGTAGTGTG GGTGCGGAAA GGCCTTGTGG TACTGCCIGA TAGGGTGCTT GCGAGTGCCC	300
30	CGGGAGGTCT CGTAGACCGT GCACCATGAG CACAAATCCT AAACCTCAAA GAAAAACCAA	360
	ACGTAACACC AACCGCCGCC CACAGGACGT CAAGTTCCTG GCGGTGGTIC AGATCGTTGG	420
	TGGAGTTTAC CTGTTGCCGC GCAGGGGCCC CAGGTTGGGT GTGCGCGCGA CTAGGAAGAC	480
35	TTCCGAGCGG TCGCAACCTC GTGGAAGGCG ACAACCTATC CCCAAGGCTC GCCGGCCCCG	540
	GGGCAGGGCC TGGGCTCAGC CCGGTACCC TTGGCCCCC TATGGCAATG AGGGTCTTGG	600
	GTGGGCAGGA TGGCTCCTGT CACCCCGAGG CTCICGGCCT AGCTGGGGCC CCACTGACCC	660
40	CCGGCGTAGG TCGCGTAATT TGGGTAAGGT CATCGATACC CTCACATGCG GCTTCGCCGA	720
	CCTCATGGGG TACATTCCGC TCGTCGGCGC CCCCCTGGGA GGCGCTGCCA GGGCCCTGGC	780
45	GCAATGGCGTC CGGGTTCCTG AACACGG	807

SEQ ID NO: 11

SEQUENCE LENGTH: 20 base pairs

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: Single

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid, synthesized DNA  
 ANTI-SENSE: Yes

5

SEQUENCE DESCRIPTION  
 AAGATAGAGA AAGAGCAACC

10

20

SEQ ID NO: 12  
 SEQUENCE LENGTH: 20 base pairs  
 SEQUENCE TYPE: nucleic acid  
 STRANDEDNESS: Single  
 TOPOLOGY: linear

15

20

MOLECULE TYPE: Other nucleic acid, synthesized DNA  
 ANTI-SENSE: No

25

SEQUENCE DESCRIPTION  
 GGCGACACTC CACCATAGAT

30

20

SEQ ID NO: 13  
 SEQUENCE LENGTH: 20 base pairs  
 SEQUENCE TYPE: nucleic acid  
 STRANDEDNESS: Single  
 TOPOLOGY: linear

35

40

MOLECULE TYPE: Other nucleic acid, synthesized DNA  
 ANTI-SENSE: No

45

SEQUENCE DESCRIPTION  
 GGCGACACTC CACCATAGAT

50

20

SEQ ID NO: 14  
 SEQUENCE LENGTH: 20 base pairs

55

SEQUENCE TYPE: nucleic acid  
STRANDEDNESS: Single  
5 TOPOLOGY: linear  
MOLECULE TYPE: Other nucleic acid, synthesized DNA  
10 ANTI-SENSE: Yes

SEQUENCE DESCRIPTION  
15 CCGTGTTC CA GAACCCGGAC 20

SEQ ID NO: 15  
20 SEQUENCE LENGTH: 20 base pairs  
SEQUENCE TYPE: nucleic acid  
STRANDEDNESS: Single  
25 TOPOLOGY: linear  
MOLECULE TYPE: Other nucleic acid, synthesized DNA  
30 ANTI-SENSE: Yes

SEQUENCE DESCRIPTION  
35 CATGGTGCAC GGTCTACGAG 20

SEQ ID NO: 16  
40 SEQUENCE LENGTH: 20 base pairs  
SEQUENCE TYPE: nucleic acid  
STRANDEDNESS: Single  
45 TOPOLOGY: linear  
MOLECULE TYPE: Other nucleic acid, synthesized DNA  
ANTI-SENSE: No  
50

SEQUENCE DESCRIPTION  
55 ACTCCACCAT AGATCACTCC 20

SEQ ID NO: 17

5

SEQUENCE LENGTH: 24 base pairs

SEQUENCE TYPE: nucleic acid

10

STRANDEDNESS: Single

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid, synthesized DNA

15

SEQUENCE DESCRIPTION

GAGTGTCGTG CAGCTCCAG GTCC

24

20

#### Claims

25

1. A DNA sequence comprising a DNA sequence designated by SEQ ID NO: 1, SEQ ID NO: 5, or SEQ ID NO: 10.

2. A DNA sequence according to claim 1, which is the DNA sequence designated by SEQ ID NO: 1, SEQ ID NO: 5, or SEQ ID NO: 10.

30

3. A method for the detection of hepatitis C virus, which is based on the PCR technique characterized by using a primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 2 and a primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 3; or using a primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 15 and a primer composed of from 15 to 40 bases including at least 15 straight bases in the DNA sequence designated by SEQ ID NO: 16.

35

40

45

50

55